Pancreatic Cancer Therapeutics & Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Type, By End-User By Region & Competition, 2020-2030F

Description

Global Pancreatic Cancer Therapeutics & Diagnostics Market was valued at USD 4.60 Billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 7.50% through 2030. The Global Pancreatic Cancer Therapeutics & Diagnostics Market is a dynamic and evolving sector of the healthcare industry, driven by the urgent need to combat one of the deadliest forms of cancer.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 4.60 Billion
Market Size 2030	USD 7.12 Billion
CAGR 2025-2030	7.50%
Fastest Growing Segment	Treatment
Largest Market	North America

Pancreatic cancer is a relatively rare cancer, accounting for a small percentage of all cancer cases. However, it is one of the most lethal forms of cancer, with a low survival rate. The incidence of pancreatic cancer varies by region, with some areas experiencing higher rates than others. Risk factors include age, family history, smoking, obesity, and certain genetic mutations.

Key Market Drivers

Rising Incidence of Pancreatic Cancer

The increasing incidence of pancreatic cancer is a major driving force behind the expansion of the Global Pancreatic Cancer Therapeutics & Diagnostics Market. Pancreatic cancer remains one of the most lethal malignancies, posing a significant challenge to global healthcare systems. In 2020, approximately 500,000 new cases were reported worldwide, with 470,000 fatalities, underscoring the disease's high mortality rate. The global incidence rate stood at 4.9 cases per 100,000 people, while the mortality rate reached 4.5 per 100,000, highlighting the urgent need for more effective diagnostic and therapeutic interventions. This trend is influencing the demand for advanced treatment options, early diagnostic solutions, and improved healthcare infrastructure. Pancreatic cancer is among the most aggressive malignancies, with a high mortality rate. Due to late-stage diagnoses and limited treatment options, the survival rate remains low. The five-year survival rate for pancreatic cancer varies significantly based on the stage at diagnosis. For patients diagnosed at an early, operable stage, the survival rate reaches 20%. However, when considering all cases-including advanced, inoperable stages-the overall five-year survival rate drops to just 5%. The rising number of diagnosed cases worldwide is directly fueling the demand for innovative therapeutic solutions, including chemotherapy, immunotherapy, targeted therapy, and personalized medicine.

Key Market Challenges

High Treatment Costs

Pancreatic cancer treatment can be prohibitively expensive. The disease often necessitates aggressive interventions, including surgery, chemotherapy, radiation therapy, and personalized targeted therapies. These treatments not only involve substantial direct medical costs but also indirect costs related to hospitalization, supportive care, and managing side effects. Additionally, the complexity of pancreatic cancer cases often requires specialized healthcare providers and facilities, further driving up costs.

High treatment costs pose financial burdens on patients, healthcare systems, and insurers. This can limit patient access to advanced therapies and diagnostics, impacting market growth. Moreover, it can lead to delays in seeking treatment and influence treatment choices based on cost considerations rather than optimal clinical outcomes.

Key Market Trends

Advancements in Personalized Medicine

Personalized medicine is a significant trend in the treatment of pancreatic cancer. This approach tailors treatment plans based on an individual patient's genetic makeup, tumor characteristics, and other factors. Advancements in genomics and molecular profiling technologies have made it possible to identify specific mutations and biomarkers associated with pancreatic cancer. This trend is driven by the need for more effective and targeted therapies, as standard treatments have shown limited success in improving survival rates for pancreatic cancer patients.

The adoption of personalized medicine is expanding the range of therapeutic options available in the market. Pharmaceutical companies are developing targeted therapies that address specific genetic mutations, offering new hope for patients. Diagnostic tools that enable genetic profiling and guide treatment decisions are also in high demand. This trend is expected to drive market growth as more personalized treatment approaches become available.

Key Market Players

Myriad Genetics Inc.
Pfizer Inc.
Novartis AG
Bristol-Myers Squibb Company
AstraZeneca PLC
Amgen Inc.
Viatris Inc.
Boston Scientific Corporation
FUJIFILM Holdings Corporation
Canon Inc. (canon Medical Systems Corporation)
Rafael Holdings Inc

Report Scope:

In this report, the Global Pancreatic Cancer Therapeutics & Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pancreatic Cancer Therapeutics & Diagnostics Market, By Type:

Treatment
Diagnostics

Pancreatic Cancer Therapeutics & Diagnostics Market, By End User:

Hospitals & Clinics
Ambulatory Centers
Others

Pancreatic Cancer Therapeutics & Diagnostics Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pancreatic Cancer Therapeutics & Diagnostics Market.

Available Customizations:

Global Pancreatic Cancer Therapeutics & Diagnostics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Type (Treatment {Targeted Therapies, Chemotherapy, Surgery, Other}, Diagnostics {Imaging, Biopsy, Endoscopic Ultrasound, Other})
- 5.2.2. By End-User (Hospital & Clinic, Ambulatory Centers, Others)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
5.3. Market Map

6. North America Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Type
- 6.2.2. By End User
- 6.2.3. By Country
6.3. North America: Country Analysis
- 6.3.1. United States Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Type
    - 6.3.1.2.2. By End User
- 6.3.2. Canada Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Type
    - 6.3.2.2.2. By End User
- 6.3.3. Mexico Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Type
    - 6.3.3.2.2. By End User

7. Europe Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type
- 7.2.2. By End User
- 7.2.3. By Country
7.3. Europe: Country Analysis
- 7.3.1. Germany Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Type
    - 7.3.1.2.2. By End User
- 7.3.2. United Kingdom Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Type
    - 7.3.2.2.2. By End User
- 7.3.3. Italy Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Type
    - 7.3.3.2.2. By End User
- 7.3.4. France Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Type
    - 7.3.4.2.2. By End User
- 7.3.5. Spain Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Type
    - 7.3.5.2.2. By End User

8. Asia-Pacific Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type
- 8.2.2. By End User
- 8.2.3. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type
    - 8.3.1.2.2. By End User
- 8.3.2. India Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type
    - 8.3.2.2.2. By End User
- 8.3.3. Japan Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type
    - 8.3.3.2.2. By End User
- 8.3.4. South Korea Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Type
    - 8.3.4.2.2. By End User
- 8.3.5. Australia Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Type
    - 8.3.5.2.2. By End User

9. South America Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type
- 9.2.2. By End User
- 9.2.3. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type
    - 9.3.1.2.2. By End User
- 9.3.2. Argentina Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type
    - 9.3.2.2.2. By End User
- 9.3.3. Colombia Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type
    - 9.3.3.2.2. By End User

10. Middle East and Africa Pancreatic Cancer Therapeutics & Diagnostics Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type
- 10.2.2. By End User
- 10.2.3. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type
    - 10.3.1.2.2. By End User
- 10.3.2. Saudi Arabia Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type
    - 10.3.2.2.2. By End User
- 10.3.3. UAE Pancreatic Cancer Therapeutics & Diagnostics Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type
    - 10.3.3.2.2. By End User

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Developments
12.2. Product Launches
12.3. Mergers & Acquisitions

13. Global Pancreatic Cancer Therapeutics & Diagnostics Market: SWOT Analysis

14. Competitive Landscape

14.1. Myriad Genetics Inc.
- 14.1.1. Business Overview
- 14.1.2. Product & Service Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (If Listed)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
14.2. Pfizer Inc.
14.3. Novartis AG
14.4. Bristol-Myers Squibb Company
14.5. AstraZeneca PLC
14.6. Amgen Inc.
14.7. Viatris Inc.
14.8. Boston Scientific Corporation
14.9. FUJIFILM Holdings Corporation
14.10.Canon Inc. (canon Medical Systems Corporation)
14.11.Rafael Holdings Inc.